Drug Profile
Research programme: tolerogenic dendritic vaccines - Idogen
Alternative Names: IDO TLatest Information Update: 09 May 2022
Price :
$50
*
At a glance
- Originator Idogen; Lund University
- Class Cell therapies; Dendritic cell vaccines
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Autoimmune disorders; Renal transplant rejection
Most Recent Events
- 04 May 2022 Preclinical development for Renal transplant rejection(Prevention) is ongoing in Sweden (IV, Infusion)
- 13 Dec 2019 Idogen files for patent protection with the Intellectual Property Office in the UK for tolerogenic dendritic cell therapy
- 20 Aug 2019 Idogen plans a clinical trial for IDO T in Renal transplant rejection (Prevention) in 2022